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LETTERS
Sinusoidal dilatation: a rare side effect of azathioprine
A M Jacobi, E Feist, B Rudolph, G R Burmester
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ann Rheum Dis 2004;63:1702–1703. doi: 10.1136/ard.2003.017855
H
epatotoxicity is an often reported side effect of
azathioprine treatment, which requires monitoring of
serum transaminases and c-glutamyltransferase (c-
GT), especially during the first 6 months of treatment. This
case report, however, illustrates that side effects of azathio-
prine can also occur after a longer period of treatment. We
report a case of sinusoidal dilatation as a rare side effect of
azathioprine treatment in a patient with systemic sclerosis.
CASE REPORT
A 50 year old female patient with systemic sclerosis presented
with a rapid increase of body weight (approximately 5 kg
within 3 days) and abdominal circumference, diffuse abdom-
inal pain, oedema of the lower extremities, dyspnoea, tachy-
cardia, and low blood pressure (90/60 mm Hg). Because
systemic sclerosis with pulmonary involvement had been
diagnosed 1K years previously, the patient received azathio-
prine (2 mg/kg) and prednisone (5 mg) daily. The patient
tested positive for anti-PM/Scl (anti-exosomal) antibodies.
Furthermore, protein C and S deficiency and occlusions of
various finger arteries of the left hand were diagnosed.
Therefore she has been treated with warfarin during the past
18 months and received intravenous iloprost intermittently.
Treatment was tolerated without any side effects and
3 months before admission to the hospital clinical examina-
tion and laboratory measures were completely normal.
The laboratory tests at admission, however, disclosed a pan-
cytopenia (leucocytes 2.046109/l, platelets 446109/l, erythro-
cytes 2.0261012/l) increased c-GT (90 U/l (normal ,38)) and
bilirubin (38 mmol/l (normal ,18)), and signs of haemolysis
with raised lactate dehydrogenase (323 U/l (normal ,247))
and free haemoglobin. Liver function was only mildly impaired
(antithrombin III 67% (normal 70–130), pseudocholinesterase
normal, slightly reduced albumin). Serum transaminases were
moderately raised. Of note, there were no signs of any previous
hepatic disease in the patient’s history.
Ultrasound examination of the abdomen showed ascites; a
thrombosis of the liver veins or portal vein was excluded.
There were no characteristic signs of longstanding portal
hypertension in the ultrasound examination (normal dia-
meter of the portal vein and normal size of the spleen).
However, ultrasonographic signs of liver steatosis were
present. A computed tomographic scan of the abdomen
showed fibrosis of the liver and a venous perfusion block.
Warfarin was replaced by heparin. Azathioprine was
discontinued. After a mild diuretic treatment (40 mg
furosemide and 25 mg spironolactone/day), ascites comple-
tely disappeared within 3 days. A slight increase of haemo-
globin, leucocyte, and platelet count and decrease of lactate
dehydrogenase occurred spontaneously at the end of the first
week of observation, whereas the c-GT remained constant.
After the recovery of platelet counts, bone marrow and
liver were biopsied. The histology showed left shifted
granulopoiesis and erythropoiesis as well as megablastoid
transformed erythrocytes and disturbed megakaryopoiesis.
This is in line with bone marrow damage related to drug
toxicity with signs of beginning regeneration. The liver tissue
was free of inflammation and showed non-continuous
infiltrative fibrosis without bridges or remodelling of the
liver tissue. Signs of a venous block without central venulitis
or clots were reported (fig 1). Sinusoidal dilatation was the
predominant pathological finding.
DISCUSSION
Liver biopsy was performed to localise the venous perfusion
block in more detail and to rule out Budd-Chiari syndrome,
which had to be considered as a differential diagnosis.1
Sinusoidal dilatation and veno-occlusive disease (VOD) are
vascular disorders of the liver associated with azathioprine
treatment. Sinusoidal dilatation is assumed to be an early
and less severe form of VOD, a liver disease also seen in
patients after stem cell transplantation.2 In contrast with
sinusoidal dilatation, VOD is characterised by additional
affection of the central venules.3 Azathioprine possibly causes
a depletion of glutathione in the endothelial cells. This
mechanism has been described for murine sinusoidal
endothelial cells.4 After endothelial injury subendothelial
oedema causes congestion of sinusoids in a non-thrombotic
manner. Sinusoidal dilatation has also been seen in patients
after kidney transplantation.5 These patients had been
receiving azathioprine for about 16–24 months before the
onset of symptoms. After 1–3 years, fibrosis or micronodular
cirrhosis had developed.
This case illustrates that also after longlasting treatment
with azathioprine severe side effects may occur and, there-
fore, these patients should be continuously monitored.
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Tick bite fever and arthritis associated with travel to Africa
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CASE REPORT
A 52 year old woman was admitted with fever and acute
polyarthritis. She had visited a game reserve in Northern
Province, South Africa 5 weeks before admission. Two weeks
before admission she developed fever and flu-like symptoms,
then mouth ulcers, and a non-itchy, maculopapular rash that
covered her whole body and her scalp. Three days after the
start of the rash she developed painful and swollen joints—
notably, the hands, elbows, wrists, knees, and feet.
On examination at admission she was apyrexial with no
visible rash and no lymphadenopathy. She had florid
synovitis at elbows, wrists, knees, and dactylitis affecting
the right index finger (fig 1A), left thumb, and left 4th toe.
Spinal movement was normal. Examination was otherwise
unremarkable.
The full blood count and renal function were normal,
erythrocyte sedimentation rate 131 mm/1st h and C reactive
protein (CRP) 324 mg/l (normal ,6 mg/l). A chest radio-
graph, and x ray examination of hands, feet, and sacroiliac
joints were normal. A 99mTc-MDP bone scan showed
increased uptake over the elbows, wrists, tarsi, left 1st
interphalangeal joint and 4th proximal interphalangeal
joints, and right 2nd and 3rd metacarpophalangeal joints
(fig 1B). Antinuclear antibodies, rheumatoid factor, HLA-
B27, hepatitis A and B, brucella, coxiella, chlamydia,
parvovirus, and arbovirus serology were all negative, as was
stool culture for salmonella, shigella, and campylobacter. It
was confirmed that the patient’s serum contained anti-
rickettsia ‘‘spotted fever group’’ antibody, titre 1/640, by
screening using sheep red blood cells sensitised with spotted
fever group specific antigen in an immune-haemagglutina-
tion assay.1
Doxycline was started empirically before the rickettsial
serology result was known, and continued for 3 weeks.
Intramuscular depomedrone 120 mg produced little improve-
ment in joint symptoms and CRP. After 2 weeks sulfasalazine
and oral prednisolone 15 mg daily were started; marked and
continuing improvement followed despite rapid tapering of
the steroid dosage.
The incubation period of rickettsial disease is 1 to 2 weeks,
followed by abrupt onset of malaise, headache, and fever. An
eschar is sometimes visible at the site of tick bite. A
maculopapular or petechial rash is present usually on days
7 to 10 after the bite.
DISCUSSION
African tick bite fever has been recognised since the
beginning of the 20th century as a rural disease, contracted
from ticks of cattle and game. Initially, the condition was
thought to be exclusively due to Rickettsia conorii. The first
human infection with R africae was reported from Zimbabwe
only in 1992. Recently R africae has also been identified in
Amblyomma ticks from Niger, Mali, Burundi, and Sudan.2
Arthralgias occur commonly during rickettsial infections,
but arthritis is rare and is usually acute aseptic monarthritis
of a large joint. However, pauci- and polyarthritis have also
been described.3 There have been 12 previous reports of
arthritis with Mediterranean spotted fever,2 caused by R
conorii, and there has been only a single case report of
arthritis associated with Rocky Mountain spotted fever.4 As
far as we know, this is the first reported case of arthritis in
association with spotted fever (R africae and R conorii)
originating from South Africa.
Figure 1 Dactylitis affecting the right
index finger (A) and 99mTc-MDP bone
scan showing increased uptake over
both wrists, left 1st interphalangeal joint
and 4th proximal interphalangeal joints
and right 2nd and 3rd
metacarpophalangeal joints (B).
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Between 1998 and 2002 spotted fever predominately due to
R africae was detected in 131 cases (four with arthralgia)
returning from southern Africa to the UK. More cases may be
seen world wide if southern Africa continues to develop as a
tourist destination.
In conclusion, we have described a patient who developed
polyarthritis owing to rickettsial disease acquired in South
Africa. Diagnosis was made based on the clinical history and
the presence of anti-spotted fever group antibodies.
Rickettsial infection should be included in the differential
diagnosis of acute aseptic arthritis in travellers returning
from sub-Saharan Africa5; effective treatment with tetra-
cycline may otherwise be overlooked.
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Extracorporeal shock wave therapy in the treatment of
inferior calcaneal enthesophytosis: outcome by fan-beam
dual x ray absorptiometry (DXA)
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P
lantar fasciitis with heel spurs is a common cause of heel
pain, and is often not sensitive to conservative treat-
ment, including insole supports, non-steroidal anti-
inflammatory drugs, local steroid injection, and physical
therapy.1 2 In patients in whom conservative treatment fails,
surgical intervention is recommended.3
Recently, extracorporeal shock wave therapy has been
introduced for the alleviation of painful heel and other
conditions such as tennis elbow, calcifying tendinopathy of
the shoulder, and non-union of fractures of the long bones.4–7
The presence and size of the heel spurs do not correlate
with the clinical symptoms.4 8
Twenty patients aged between 40 and 70 years were
treated. Exclusion criteria were degenerative diseases and/or
inflammation of the ankle or foot joints, neurological
abnormalities, nerve entrapment syndrome, pregnancy,
infectious or neoplastic diseases, ulcerations, and bursitis.
Inclusion criteria were painful heel for a minimum of
12 months with heel spur radiologically examined and
unsuccessful conservative treatment during the 6 months
before referral to our hospital. No other treatment or drug
was used during the 4 weeks before the trials began or during
the study period, only the use of insole supports was
permitted. An electrohydraulic system was used (Orthima;
Direx Medical System Ltd).
Five treatments were given (one every 7 days), each
treatment comprising 1200 shocks with a frequency of 120
shocks a minute. As the treatment may be initially painful,
the energy density used on starting treatment was 0.03 mJ/
mm2, which was gradually increased to 0.4 mJ/mm2.
Variations in the bone mineral content (BMC) of enthe-
sophytosis were evaluated by fan-beam dual x ray absorptio-
metry (DXA) using a Lunar-Expert version 1.72, at baseline
and 1 month after the end of treatment.9 This method allows
rapid scanning of particular skeletal regions, and provides a
radiographic-like image.10 Scans of 1 mA were applied to the
heel, the foot was placed in complete extra-rotation, using a
plastic support specific for a DXA evaluation of small bone
structures. A region of interest was created in each patient,
with a side at the base of the enthesophytosis, to include the
enthesophytosis and to exclude the os calcis cortex; this
region of interest remained unchanged for later controls
(fig 1). The short term precision of the method was 0.5%
(coefficient of variation) in vivo, as calculated in 10 patients
scanned four times.
Pain levels were evaluated (before treatment, at the end of
treatment, and 3 and 6 months later) by visual analogue
scale (VAS) ranging from 0=no pain to 10=maximum pain,
Figure 1 Fan-beam DXA of the heel.
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at rest, after walking on awakening, and after normal daily
activity. A significant decrease of VAS (p,0.0001, Wilcoxon
test) was seen (table 1).
DXA analysis of enthesophytosis showed a significant
decrease in BMC (p,0.001, paired Student’s t test) from an
average of 0.162 g to a mean of 0.111 g.
In conclusion, we found that extracorporeal shock wave
therapy significantly improved the painful symptoms; in our
study this reduction in pain was accompanied by a significant
decrease of the BMC of the heel spur.
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Table 1 Pain levels
Mean VAS at rest
Mean VAS after walking
on awakening
Mean VAS after normal
daily activity
(range 0–10) (range 0–10) (range 0–10)
Basal 8.1 (1.5) 8.1 (1.4) 8.3 (1.2)
End of the treatment 5.9 (1.2) 6.7 (1.6) 5.6 (1.8)
After 3 months 4.3 (1.6) 6.1 (1.3) 4.1 (1.8)
After 6 months 4.1 (1.5) 3.9 (1.6) 3.6 (1.7)
Results are shown as mean (SD).
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M
aternal and fetal outcome of pregnancy in patients
with systemic lupus erythematosus (SLE) depends
very much on the composition of the patient cohort
being analysed.
METHODS AND RESULTS
We performed a retrospective study to identify the clinical
predictive factors for unfavourable pregnancy outcome in our
Chinese patients with SLE from a homogeneous cohort being
followed up at the university rheumatology clinic during the
period 1982–96. Ninety one pregnancies from 66 patients
were identified. Antiphospholipid antibodies (aPL), including
lupus anticoagulant (LAC) and/or IgG anticardiolipin anti-
bodies, were present in 18/66 (27%) patients. In 33/80 (41%)
pregnancies resulting in live births, patients had a past
history of lupus nephritis. Only one patient had impaired
renal function, two had significant proteinuria >1 g/day, and
four had stable hypertension while receiving antihyperten-
sive drugs at conception. Active lupus was present within
6 months before conception in 12/91 (13%) and at conception
in 7/91 (8%) pregnancies.
The live birth rate and fetal loss rate was 80/91 (88%) and
11/91 (12%), respectively. Fetal loss was found to be
associated with serum anti-Ro (p=0.04), anti-La
(p=0.007), and significant proteinuria at conception
(p=0.03). aPL were not found to relate to a single episode
of fetal loss (p=0.06), but they were more prevalent in
patients with recurrent miscarriages (odds ratio (OR)=14.3,
p=0.008), of which LAC was the strongest predictive factor
(OR=23.3, p=0.002). Poor fetal outcome was found in 27/
80 (34%) live births. There were 13 premature births and 14
fetuses had intrauterine growth retardation (IUGR).
Significant proteinuria during pregnancy (p=0.006) and
flare in gestation (p=0.001) was found to be related to
prematurity. Multivariate analysis identified flare during
pregnancy, in particular in the second trimester, as the
strongest risk factor (relative risk (RR)=5.5, 95% confidence
interval (CI) 1.4 to 21.9, p=0.02). Active lupus both within
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6 months before (p=0.01) and at conception (p=0.002)
was found to predispose to IUGR. The latter was identified by
multivariate analysis as the most predictive factor (RR=22.1,
95% CI 2.5 to 215.1, p=0.008). Pre-eclampsia was present in
8/80 (10%) pregnancies and no particular risk factor was
found.
Thirty three pregnancies were recorded in the 27 patients
with a past history of lupus nephritis. The live birth rate, fetal
loss rate, and rate of poor fetal outcome (prematurity in four,
IUGR in six) were not particularly different from those in
patients with non-renal SLE and were 94%, 6%, and 30%,
respectively. Predictive factors for poor fetal outcome in this
subset of patients included significant proteinuria at concep-
tion (p=0.004) and during pregnancy (p=0.01) and active
SLE within 6 months before conception (p=0.007) and at
conception (p=0.03).
DISCUSSION
The fetal loss rate in our cohort lies near the lower end of the
11–46% range which was previously reported.1 This was
partly because our patients had a lower prevalence of aPL
(27%) than the 34–44% reported in other cohorts2 and partly
related to the small proportion of patients with active SLE at
conception. Better live birth rates have been reported in
patients with inactive rather than active disease at concep-
tion.3–5 Our reported rate of poor fetal outcome and the
associated risk factors were similar to those previously
reported.1 6–9 The fetal loss rate in our patients with a past
history of lupus nephritis was, however, lower than those
reported (13–46%)3 because the renal disease of our patients
was quiescent at conception; active nephritis at conception
has been reported to give a higher risk of fetal loss.10 Further-
more, patients in our clinic with impaired renal function were
generally discouraged from becoming pregnant.
In conclusion, adverse pregnancy outcome was more
common in patients with active disease in gestation. Fetal
outcome is favourable in patients with a past history of lupus
nephritis if they have normal renal function, no significant
proteinuria, and satisfactory blood pressure control.
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Temporomandibular joint pseudogout: an uncommon site
for a familiar condition
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I
t is well recognised that the temporomandibular joint
(TMJ) may be affected by rheumatoid or psoriatic
arthritides and ankylosing spondylitis. Interestingly, how-
ever, calcium pyrophosphate dihydrate (CPPD) crystal
deposition is unusual in this site, and authors of several
large case series of CPPD disease failed to report any acute
attacks affecting this joint.1 2 As far as we are aware, only
infrequent reports of CPPD crystal deposition in the TMJ
have been published.3–7 We therefore present the following
case to highlight a possible differential diagnosis for patients
presenting with TMJ pain and/or swelling.
CASE REPORT
A 57 year old man presented with an acute onset of severe
pain and swelling affecting his right TMJ, on a background of
chronic right sided TMJ discomfort. There were no associated
systemic features. The patient had a past history of hyper-
tension, hypercholesterolaemia, lumbar spine osteoarthritis,
fifty (50) pack year smoking history, and an alcohol intake of
90 g/day. There was no previous history of gout or CPPD
disease, and subsequent hand and knee x ray investigations
did not demonstrate chondrocalcinosis.
Clinical examination disclosed an uncomfortable, but
otherwise well appearing man, with a warm tender swelling
over his right TMJ associated with pain on attempting to
open the joint. Blood investigations included a normal full
blood count (haemoglobin 144 g/l, platelets 2296109/l, white
cell count 10.56109/l), C reactive protein 33 mg/l (normal
0–6 mg/l), normal electrolytes (including urate, magnesium,
phosphate, calcium, and thyroid function), mild increase of
alkaline phosphatase and c- glutamyltransferase, normal iron
studies, negative rheumatoid factor, positive antinuclear
antibody (1/320 homogeneous pattern), negative extractable
nuclear antigens, and negative antibodies to double stranded
deoxyribonucleic acid. A plain radiograph of the right TMJ
showed enlargement and irregularity of the right condylar
head, confirmed by a computed tomography scan. In
addition, synovial swelling around the TMJ, calcified loose
bodies, articular sclerosis, and erosions were demonstrated. A
joint aspirate comprised a thick, straw coloured fluid, and the
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patient proceeded to surgical irrigation of the upper and
lower compartments of the joint to exclude septic arthritis.
Synovial fluid analysis showed large numbers of leucocytes
(up to 5.96109/l and 70% polymorphs) and multiple weakly
positive birefringent calcium pyrophosphate crystals. Gram
stain and cultures were negative, thereby excluding infection.
The patient was treated with non-steroidal anti-inflam-
matory drugs (indometacin), with resolution of the acute
inflammation. Mild restriction of movement and pain have
persisted, secondary to underlying osteoarthritis, evident on
magnetic resonance imaging. The patient continues to receive
colchicine 0.5 mg twice daily and presently is unaffected by
features of CPPD disease in the TMJ or other joints.
DISCUSSION
Recognised as a distinct disease entity in the early 1960s,8
CPPD deposition disease has emerged as a heterogeneous
disorder, with clinical presentations ranging from an acute
arthritis to chronic pain secondary to degenerative cartilage
disease. Although CPPD crystal formation remains incom-
pletely understood, it is known to be influenced by a high
ionic product (calcium2+6inorganic pyrophosphate) and
tissue promoters or inhibitors of crystal nucleation and
growth.9 Prevalence increases with advancing age and the
presence of metabolic/endocrine abnormalities, such as
haemochromatosis, hypothyroidism, and hypomagnesaemia,
none of which were present in our patient.
The knee is affected in over half of all acute attacks of
CPPD disease,10 and as indicated by published reports,
primary manifestation of CPPD arthropathy in the TMJ is
relatively rare.3 7 Current available explanations do not clarify
why the TMJ is so infrequently affected despite containing a
fibrocartilage disc similar to that in the knee. It has been
suggested that this may relate to the lack of clinical
distinction between this entity and osteoarthritis of the
TMJ and the infrequent pathological examination of TMJs.3
However, these explanations appear to simply imply an
oversight of the condition and do not offer a pathophysio-
logical reasons for the infrequent involvement.
An alternative proposal suggests that the peculiar anatomy
of the adult TMJ, with its absence of hyaline cartilage in
comparison with other diarthrodial joints, is an important
contributor.3 Although the exact reason as to why the
temporomandibular joint appears to be relatively ‘‘protected’’
from CPPD crystal deposition remains to be elucidated,
clinicians should be alert to the possibility of its occurrence in
this joint. In addition, this case highlights the importance of
mandatory synovial fluid analysis for crystals in any acute
undiagnosed arthritis, to facilitate prompt diagnosis and
appropriate treatment.
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Antinuclear antibodies are common in an infectious
environment but do not predict systemic lupus
erythematosus
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T
he reasons underlying the appearance of autoantibodies
are poorly understood. The recent proposal that child-
hood infections prevent both autoantibody formation
and occurrence of autoimmune diseases1 2 led to the
suggestion that widespread vaccination against infectious
diseases might favour the development of autoimmune
diseases.2
To verify whether repeated infections from childhood
prevent autoantibody formation we compared the prevalence
of antinuclear antibodies (ANA), autoantibodies of infre-
quent occurrence in healthy controls from Western Europe
and associated with systemic lupus erythematosus (SLE) and
other autoimmune diseases, in populations with different
prevalence of infections throughout the course of life—
namely, African immigrants to Italy and Italians.
METHODS AND RESULTS
We obtained written informed consent from 137 Ghanaian or
Nigerian apparently healthy immigrants to Italy and living in
Verona (northeastern Italy), unrelated to patients with SLE
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or other autoimmune diseases, characterised by ANA
positivity. We drew blood samples which were first tested
for anti-HIV antibodies. Thirteen positive subjects were
excluded from the survey. In the remaining 124 (mean age
35, range 8–53 years; 58 women) we looked for the presence
of ANA by immunofluorescence on Hep-2 cells. We selected
anti-HIV negative subjects to exclude the influence of anti-
HIV antibody cross reactivity or HIV infection itself on the
results of ANA determination; we also excluded relatives of
patients with ANA positive autoimmune diseases because
ANA positivity is more common in this subgroup.3 4
All the subjects studied recalled at least four episodes of
malaria and three episodes of diarrhoea of at least 5 days’
duration. Hence the immigrant study population had been
exposed to repeated infections during their lifetime. The
prevalence (reciprocal titres 40–320) of ANA was found to be
very high (27.4%, comparable to that of relatives of white
patients with SLE)4 and even higher in more recent
immigrants (table 1). Of the 34 positive subjects, 17 were
women and 17 men; their mean (SD) age was 33 (8). As a
control population, we used 375 white northeastern Italian
subjects matched for age and sex and found an ANA
prevalence of 3.5% (p,0.01).
DISCUSSION
Our data strongly suggest that living in an ‘‘infectious’’
environment from early life does not prevent, but rather
favours, the formation of ANA. Although the reasons
underlying their appearance are obscure, a role for a
molecular mimicry between nuclear components of normal
cells and parasitic or viral antigens cannot be excluded, as
this has been demonstrated with the hepatitis B virus DNA
polymerase.5
The finding that ANA positivity is far higher in recent
immigrants is intriguing, as they are younger and therefore
expected to have a lower incidence of autoantibodies than
older subjects. Furthermore, although ANA are more
frequently detected in women, we did not observe a
preponderance in the female immigrant population tested.
Although a definitive demonstration would require repeated
testing of immigrants and demonstration of loss of ANA
positivity over time, the present findings do suggest that the
longer a person lives in a ‘‘less infectious’’ environment, the
higher is the probability that they will be autoantibody
negative.
Interestingly, none of the ANA positive subjects have
developed any symptoms of autoimmune diseases in a mean
follow up of 18 months.
In conclusion, our data demonstrate that markers of
autoimmunity, such as ANA, are frequently found in
Africa-born people but tend to be lost if they live for a long
time in Western countries. Their presence should not there-
fore be regarded as predictive of SLE, a conclusion which
confirms findings from studies in developed countries.6
Prospective epidemiological studies are needed both in
developed and developing countries if the real mechanisms
leading to overt autoimmune diseases are to be understood.
Meanwhile, vaccination programmes in developing countries
can continue without any concerns about a possible increase
in the incidence of autoimmune diseases.
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Table 1 Prevalence of antinuclear antibodies (ANA) in Italian healthy controls, and in
immigrants from West Africa to Italy according to age and length of residence in Italy
Italian healthy
controls
Subjects who left Africa
Total number
of Africa-
born subjects
3 months–
7 years ago
8–14 years
ago
15–21 years
ago
Number 375 68 42 14 124
Age, mean (SD) 30 (15) 31 (7) 38 (6) 45 (5) 35 (8)
ANA positive, No (%) 13 (3.5) 24 (35) 8 (19) 2 (14) 34 (27)
Reciprocal ANA titres,
median (range)
40 (0–160) 80 (40–320) 40 (40–160) 40 (40) 40 (40–320)
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